Compare Incyte Corporation (INCY) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs JetBlue Airways Corporation — how do they compare? Incyte Corporation trades at $121.36 (market cap $24.54B), while JetBlue Airways Corporation trades at $5.86 (market cap $2.19B). The key difference: Incyte Corporation is far larger — about 11.2× JetBlue Airways Corporation's market cap. Which is the better fit depends on your goals.
| INCY | JBLU | |
|---|---|---|
Market Cap | $24.54B | $2.19B |
Sector | Health | Industrials |
52-Week High | $129.93 | $6.46 |
52-Week Low | $81.61 | $4.03 |
Enterprise Value | $20.04B | $9.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
JetBlue (JBLU) trades at $5.87, up 4.08% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings beat with a loss of $0.66 per share versus expectations of $0.69, though it has missed estimates in two of the last three quarters. Recent news includes Citigroup's downgrade to Sell on August 11, 2026, citing geopolitical risks, while the company introduced new fare structures and lounge accolades.
Outlook remains challenging with persistent net losses and negative margins, but cost management and strategic initiatives like the 2028 profit target offer potential upside. Key risks include high fuel costs, debt levels, and competitive pressure. Analyst consensus is cautious with a $5.18 price target and 62% Hold ratings, suggesting limited near-term growth amid operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
